Search
forLearn
5 / 801 resultslearn Selenium AAC
learn HT-B
learn EUK 134
learn acetyl cysteine
Research
5 / 90 resultsresearch Atypical post-finasteride syndrome: A pharmacological riddle
Finasteride and dutasteride can cause severe, lasting side effects.
research Reversible Vision Loss With Pituitary Microadenoma Following PRP Injection for Hair Growth: A Rare Case Report and a Mini‐Review of the Literature
PRP injection for hair growth can cause reversible vision loss due to inflammatory optic neuropathy.
research Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
Biologics for severe asthma have known side effects, but some new risks need more study.
research Suspected adverse reactions to medications and food supplements containing Serenoa repens: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports
Serenoa repens is mostly safe but has some risks, especially at high doses or when used with other products for over two weeks.
research Amitriptyline-induced Telogen Effluvium in a Patient with Cervical Disc Prolapse: A Case Report
Amitriptyline can cause temporary hair loss, which stops after discontinuing the drug.
Community Join
5 / 1000+ resultscommunity HMI 115 hasn't done phase one yet for AGA?
User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community The theory that explains everything. Community Crowdfund
3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community cb-03-01 research chem (winlevi/clascoterone cream)
The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.